Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
This study has been terminated.
(Recommendation of DSMB for safety issue, increased mortality with study drug.)
Sponsor:
Ontario Clinical Oncology Group (OCOG)
Collaborator:
Ortho Biotech Products, L.P.
Information provided by:
Ontario Clinical Oncology Group (OCOG)
ClinicalTrials.gov Identifier:
NCT00310232
First received: March 31, 2006
Last updated: June 29, 2007
Last verified: March 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The general objective of this study is to improve the Quality of Life (QoL) of selected patients with advanced carcinoma of the lung. The specific objective is to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) on anemia related QoL and anemia in non-small cell lung cancer patients with advanced stage disease and underlying anemia of malignancy.
| Condition | Intervention | Phase |
|---|---|---|
|
Non-Small-Cell Lung Carcinoma Lung Cancer Anemia |
Drug: Epoetin Alfa |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) |
Resource links provided by NLM:
Further study details as provided by Ontario Clinical Oncology Group (OCOG):
Primary Outcome Measures:
- Change in anemia and fatigue related QoL at 12 weeks following randomization [ Time Frame: 12 weeks following randomization ]
Secondary Outcome Measures:
- Overall QoL and domain-specific QoL scores [ Time Frame: 16 weeks following randomization ]
- hemoglobin and hematocrit levels [ Time Frame: 6 months from randomization ]
- number of transfusions [ Time Frame: 6 months from randomization ]
| Enrollment: | 70 |
| Study Start Date: | February 2001 |
| Study Completion Date: | April 2004 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically confirmed non-small cell lung cancer (squamous cell, large cell, adenocarcinoma, or some combination of these), with clinical or pathological stage III or IV, or recurrent disease; and
- Hemoglobin level at or below 120 g/L; and
- At least 18 years of age;
Exclusion Criteria:
- Systemic platinum-based chemotherapy for lung cancer during the previous two months or planned platinum-based chemotherapy within the next three months;
- Patients previously treated with high dose thoracic radiation (>10 fractions), or surgery, without objective evidence of disease recurrence;
- Planned high dose thoracic radiation therapy (>10 fractions);
- A clinically active malignancy, other than the underlying lung cancer which is expected to influence QoL;
- Expected survival of three months or less;
- ECOG Performance status of 3 or 4 (see Appendix D);
- Multiple CNS metastasis or a single CNS lesion that does not demonstrate radiographic stability (Screening CT of head required only if symptomatic, no radiographic follow-up of single resected lesions required);
- Blood transfusions within the last 14 days;
- Previous use of erythropoietin;
- Anemia due to factors other than cancer / radiotherapy (e.g. hemolysis or gastrointestinal bleeding);
- Evidence of untreated folate or vitamin B12 deficiency;
- History of uncontrolled hypertension or diastolic blood pressure greater than 100 mm Hg;
- History of seizure disorder;
- Known hypersensitivity to mammalian cell-derived products, albumin or any component of the study drug;
- Pregnancy, lactation or parturition within the previous 30 days;
- Unwillingness or inability to complete the required QoL questionnaires;
- Mental incompetence, including psychiatric or addictive disorders which would preclude meaningful completion of questionnaires;
- Geographically inaccessible for treatment or follow-up evaluations;
- Currently enrolled in an ongoing therapeutic study;
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00310232
Locations
| Canada, Alberta | |
| Tom Baker Cancer Centre | |
| Calgary, Alberta, Canada, T2N 4N2 | |
| Cross Cancer Institute | |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Canada, Manitoba | |
| Cancer Care Manitoba | |
| Winnipeg, Manitoba, Canada, R3E 0V9 | |
| Canada, New Brunswick | |
| St. John Regional Hospital | |
| St. John, New Brunswick, Canada, E2L 4L2 | |
| Canada, Newfoundland and Labrador | |
| Newfoundland Cancer Treatment & Research Foundation | |
| St. John's, Newfoundland and Labrador, Canada, A1B 3V6 | |
| Canada, Nova Scotia | |
| Nova Scotia Cancer Centre | |
| Halifax, Nova Scotia, Canada, B3H 1V7 | |
| Canada, Ontario | |
| Hamilton Regional Cancer Centre (Juravinski) | |
| Hamilton, Ontario, Canada, L8V 5C2 | |
| London Regional Cancer Centre | |
| London, Ontario, Canada, N6A 4L6 | |
| Hotel Dieu Hospital | |
| St. Catherines, Ontario, Canada, L2K 5K3 | |
| Northeastern Ontario Regional Cancer Centre | |
| Sudbury, Ontario, Canada, P3E 5J1 | |
| Toronto East General Hospital | |
| Toronto, Ontario, Canada, M4C 3E7 | |
| Princess Margaret Hospital | |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Toronto Sunnybrook Regional Cancer Centre | |
| Toronto, Ontario, Canada, M4N 3M5 | |
| Windsor Regional Cancer Centre | |
| Windsor, Ontario, Canada, N8W 2X3 | |
| Canada, Quebec | |
| McGill University Clinical Trials Operations | |
| Montreal, Quebec, Canada, H2W 1S6 | |
Sponsors and Collaborators
Ontario Clinical Oncology Group (OCOG)
Ortho Biotech Products, L.P.
Investigators
| Study Chair: | Jim Wright, MD | Hamilton Regional Cancer Centre |
| Study Director: | Mark Levine, MD | Ontarion Clinical Oncology Group |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00310232 History of Changes |
| Other Study ID Numbers: | CTA-Control-076080, HC File 9427-J0921-22C |
| Study First Received: | March 31, 2006 |
| Last Updated: | June 29, 2007 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Ontario Clinical Oncology Group (OCOG):
|
Quality of Life Blood transfusion |
Additional relevant MeSH terms:
|
Anemia Carcinoma Carcinoma, Non-Small-Cell Lung Lung Neoplasms Hematologic Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms |
Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Epoetin Alfa Hematinics Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013